Benabdelkamel Hicham, Alamri Hanadi, Okla Meshail, Masood Afshan, Abdel Jabar Mai, Alanazi Ibrahim O, Alfadda Assim A, Nizami Imran, Dasouki Majed, Abdel Rahman Anas M
Proteomics Resource Unit, Obesity Research Center, College of Medicine, King Saud University, PO. Box 2925 (98), Riyadh 11461, Saudi Arabia.
Department of Biochemistry and Molecular Medicine,College of Medicine, Al Faisal University, Riyadh 11461, Saudi Arabia.
Int J Mol Sci. 2020 Oct 8;21(19):7415. doi: 10.3390/ijms21197415.
Cystic fibrosis (CF), the most common lethal autosomal recessive disorder among Caucasians, is caused by mutations in the CF transmembrane conductance regulator (CFTR) chloride channel gene. Despite significant advances in the management of CF patients, novel disease-related biomarkers and therapies must be identified. We performed serum proteomics profiling in CF patients ( = 28) and healthy subjects ( = 10) using the 2D-DIGE MALDI-TOF proteomic approach. Out of a total of 198 proteins identified, 134 showed a statistically significant difference in abundance and a 1.5-fold change (ANOVA, < 0.05), including 80 proteins with increased abundance and 54 proteins with decreased abundance in CF patients. A multiple reaction monitoring-mass spectrometry analysis of six differentially expressed proteins identified by a proteomic approach (DIGE-MALD-MS) showed a significant increase in C3 and CP proteins and a decrease in APOA1, Complement C1, Hp, and RBP4proteins compared with healthy controls. Fifteen proteins were identified as potential biomarkers for CF diagnosis. An ingenuity pathway analysis of the differentially regulated proteins indicates that the central nodes dysregulated in CF subjects involve pro-inflammatory cytokines, ERK1/2, and P38 MAPK, which are primarily involved in catalytic activities and metabolic processes. The involved canonical pathways include those related to FXR/RXR, LXR/RXR, acute phase response, IL12, nitric oxide, and reactive oxygen species in macrophages. Our data support the current efforts toward augmenting protease inhibitors in patients with CF. Perturbations in lipid and vitamin metabolism frequently observed in CF patients may be partly due to abnormalities in their transport mechanism.
囊性纤维化(CF)是白种人中最常见的致死性常染色体隐性疾病,由囊性纤维化跨膜传导调节因子(CFTR)氯离子通道基因突变引起。尽管在CF患者的治疗方面取得了重大进展,但仍必须确定新的疾病相关生物标志物和治疗方法。我们使用二维差异凝胶电泳-基质辅助激光解吸电离飞行时间质谱蛋白质组学方法,对28例CF患者和10名健康受试者进行了血清蛋白质组学分析。在总共鉴定出的198种蛋白质中,有134种在丰度上显示出统计学上的显著差异且变化倍数为1.5倍(方差分析,P<0.05),其中CF患者中有80种蛋白质丰度增加,54种蛋白质丰度降低。对通过蛋白质组学方法(DIGE-MALD-MS)鉴定出的6种差异表达蛋白质进行的多反应监测-质谱分析显示,与健康对照相比,C3和CP蛋白质显著增加,而载脂蛋白A1、补体C1、触珠蛋白和视黄醇结合蛋白4蛋白质减少。15种蛋白质被鉴定为CF诊断的潜在生物标志物。对差异调节蛋白质的 Ingenuity 通路分析表明,CF受试者中失调的中心节点涉及促炎细胞因子、细胞外信号调节激酶1/2(ERK1/2)和p38丝裂原活化蛋白激酶(MAPK),它们主要参与催化活性和代谢过程。所涉及的经典通路包括与法尼醇X受体/维甲酸X受体(FXR/RXR)、肝X受体/维甲酸X受体(LXR/RXR)、急性期反应、白细胞介素12、一氧化氮和巨噬细胞中的活性氧相关的通路。我们的数据支持目前在CF患者中增加蛋白酶抑制剂的努力。CF患者中经常观察到的脂质和维生素代谢紊乱可能部分归因于其转运机制的异常。